Mutant Gene Causes Increases Risk of Ovarian Cancer
Ovarian cancer is often called ‘the silent killer’ because it does not display any symptoms until the disease is too far advanced to treat. By the time that pain and bloating occur, together with changes to the bowel habits, it is often already far advanced and even at that stage is often missed because the symptoms could point to any number of other causes, thereby delaying treatment further.
A gene (RAD51D) has been identified that, in a very few women, can be faulty and lead to a six-fold increase in the risk of developing the cancer.
More than 99% of women do not carry the gene, so the research will not affect a great number of women. A mutated RAD51D gene is thought to exist in only 0.1% of women also, and having the defective gene does not by any means mean that the woman will go on to develop the cancer, only that she has a greater risk of doing so. However, the research does give scientists a greater insight into the disease and might be able to help to identify those with an increased risk, and make sure that women are given the right treatment for their particular type of cancer.
The study looked at nearly 1,000 people in families affected by cancers of the ovaries and breasts. They found that the defective gene was found in only 0.09% of the general population (i.e. those with no family history of breast or ovarian cancers) but it was more common among those families with a history of ovarian cancer.
The researchers advise that testing for the defective gene might help in identifying women with ovarian cancer. Further, if female relatives of sufferers of ovarian cancer are found to also carry the defective gene (even if they don’t have the cancer themselves), they could then be given the informed choice of whether or not to have their ovaries removed as a preventative measure.





